<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03583476</url>
  </required_header>
  <id_info>
    <org_study_id>201804076RIND</org_study_id>
    <nct_id>NCT03583476</nct_id>
  </id_info>
  <brief_title>The Impact of Antibiotics MIC Value on the Efficacy of Treatment Regimens for Helicobacter Pylori Infection.</brief_title>
  <official_title>The Impact of Antibiotics MIC Value on the Efficacy of Treatment Regimens for Helicobacter Pylori Infection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clarithromycin (CLA)、amoxicillin (AMO)、metronidazole (MET)、levofloxacin (LEV) and
      tetracycline (TET) are commonly used antibiotics for Helicobacter pylori (Hp) therapy.
      However, the efficacy of treatment for Helicobacter pylori infection has decreased due to
      increasing resistance to CLA, MET and LEV. Studies had reported that beside antibiotics
      resistance, other factors such as age, sex, underlying disease, etc. may also affect the
      treatment efficacy. In some cases, when the MIC values were beyond the breakpoint, H. pylori
      strains with lower MIC value had better eradication than the ones with higher MIC value.
      However, few study investigated the relationship between MIC values and treatment outcome.

      The investigators aimed to analyze the impact of influencing factors, especially minimal
      inhibitory concentration (MIC) value, on the efficacy of different treatment regimens.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Relationship between eradication rate (%) of therapy regimen and influencing factors (eg. sex, age, diagnosis, MIC).</measure>
    <time_frame>4 weeks after treatment finished.</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">1821</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>CLA triple therapy</arm_group_label>
    <description>Patients with clarithromycin-containing triple therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MET triple therapy</arm_group_label>
    <description>Patients with metronidazole-containing triple therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concomitant therapy</arm_group_label>
    <description>Patients with concomitant therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequential therapy</arm_group_label>
    <description>Patients with sequential therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole</intervention_name>
    <description>Triple or quadruple therapy consist of Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole.</description>
    <arm_group_label>CLA triple therapy</arm_group_label>
    <arm_group_label>Concomitant therapy</arm_group_label>
    <arm_group_label>MET triple therapy</arm_group_label>
    <arm_group_label>Sequential therapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Medical Center
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients (aged ≥ 20 years old) with H. pylori infection between Jan. 1994 to Mar. 2018

        Exclusion Criteria:

          -  without antibiotics susceptible test result, without treatment outcome, history of any
             gastrointestinal surgery, serious concomitant (renal failure, liver cirrhosis, heart
             failure and disease need immunosuppressant for therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tzu-Chi Lai, Master</last_name>
    <phone>886233668791</phone>
    <email>b01403056@g.ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tzu-Chi Lai</name>
      <address>
        <city>Taipei city</city>
        <state>No.33, Linsen S. Rd., Zhongzheng Dist</state>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tzu-Chi Lai, Master</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 22, 2018</study_first_submitted>
  <study_first_submitted_qc>July 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2018</study_first_posted>
  <last_update_submitted>July 10, 2018</last_update_submitted>
  <last_update_submitted_qc>July 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <keyword>Resistance</keyword>
  <keyword>Minimal inhibitory concentration</keyword>
  <keyword>Treatment efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

